News

Maximizing Returns: Strategies with Discounted Closed-End Funds

Maximizing Returns: Strategies with Discounted Closed-End Funds

Investment Opportunities in Today's Market

The current market is undeniably a bit daunting, hovering at all-time highs and leaving many investors feeling cautious. With fears about possible corrections, it's understandable that many are hesitant to dive in. However, staying on the sidelines might not be the best move.

Now is actually a great time to enhance your portfolio, particularly with discounted closed-end funds (CEFs), which often yield attractive returns, often above 8%.

Shift from Fear to Opportunity

It’s interesting to reflect on recent market sentiments. For instance, back in April, fear was rampant as many feared potential downturns more than they had during previous market slumps. The CNN Fear & Greed Index indicated extreme negativity, scoring at an alarming three.

This was a historic low, but as time passed, that fear transformed back into greed. The major stock indexes have recently rebounded significantly from those lows, illustrating that staying informed and engaged is crucial.

Those who chose to invest during this period of heightened fear have likely enjoyed substantial gains. Fear often deters potential investors, and overcoming this psychological barrier is essential for long-term success in the market.

Buying During Downturns

Investors often express regret over missed opportunities, and the lesson is clear: even small investments during market downturns can yield preferable outcomes compared to inaction. Maintaining a cash reserve allows for strategic buying at reduced prices during market dips.

Historical data reveals that investing on a day when the market hits an all-time high may yield better long-term results than simply investing on a random day. All-time highs tend to become new support levels, making it vital to keep an eye on these trends.

All-Time Highs and Their Significance

Reflecting on the past, significant peaks in the market have come and gone. For example, not investing at a market peak in 2013 would mean missing out on substantial gains in the years following. The lesson here is crucial: maintain active participation in the market even when prices are high, and invest more aggressively when they dip.

Unlocking Value with Discounted CEFs

This brings us to the intriguing benefits of discounted closed-end funds, like the SRH Total Return Fund (NYSE: STEW). The appeal of this fund lies in its impressive yield of 3.8%, which is significantly higher than the average yield of 1.2% seen in S&P 500 stocks.

STEW comprises well-regarded value stocks, including those favored by renowned investors. Additionally, it is currently trading at a 19.8% discount to its net asset value (NAV), providing a unique chance to acquire strong assets at reduced prices.

Long-Term Gains Await

In the past five years, STEW has delivered exceptional returns of 120%, signifying its potential for further growth. The potential for continued market peaks makes it an attractive investment for anyone looking to expand their portfolio with less volatility.

While market fluctuations may seem overwhelming, steady investments in quality assets like STEW can build wealth over time without the need to constantly monitor daily market changes.

Frequently Asked Questions

What are closed-end funds (CEFs)?

Closed-end funds are investment funds that raise capital through an initial public offering (IPO) and trade on the stock exchange, often at a discount, offering attractive yields.

Why are discounted CEFs attractive to investors?

Discounted CEFs often provide higher dividend yields, allowing investors to maximize their returns and benefit from potential capital appreciation when the market normalizes.

How can fear impact investment decisions?

Fear can lead investors to hesitate in making investment decisions, resulting in missed opportunities during market sell-offs. Overcoming this fear can enhance long-term gains.

What is the significance of market peaks?

Market peaks can indicate strong performance. However, they should not deter investments since historically, they often lead to new lows that present buying opportunities.

How do I determine the right time to invest?

While timing the market can be challenging, consistently investing over time, especially during downturns, is generally a more effective strategy than waiting for the perfect moment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading